Media Library

A cornerstone cytokine (messenger protein) involved in the development of psoriasis and other autoimmune diseases.

IL-17A helps fight infection but in chronic inflammatory joint diseases, IL-17A is a key cytokine involved in disease development.

Photo of Kymriah™ (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019.

Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness.

Kymriah® (pronounced: Kim-RYE-ah) is the first FDA-approved CAR-T cell therapy available in the US

The JULIET clinical trial is a global, multi-center Phase II registration trial investigating CTL019 (tisagenlecleucel) for use in diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma (NHL). The Novartis-sponsored JULIET trial was conducted in collaboration with the University of Pennsylvania to evaluate the safety and efficacy of CTL019 in adult patients with relapsed or refractory (r/r) DLBCL. Relapsed/refractory DLBCL is an aggressive (fast-growing), complex and difficult-to-treat disease, and patients with DLBCL often have worse prognosis than other forms of NHL.

ACZ885 is a human monoclonal antibody, which is a protein that is designed to bind to only one substance in the body. ACZ885 is designed to bind to human interleukin-1β (IL-1β).

Erenumab has been studied in several large, global, randomized, double-blind, placebo-controlled studies to assess its safety and efficancy in migraine prevention.

Erenumab is designed to specifically block the CGRP receptor, which plays a critical role in migraine activation. It is being co-developed by Novartis and Amgen.